"The combined treatment of low toxic AMPK activators, the transforming growth factor beta-activated kinase 1 (TAK1) and fatty acid synthase (FASN) inhibitors synergistically impair oncogenic augmentation of ovarian cancer. Collectively, targeting lipid metabolism signaling axis impede ovarian cancer peritoneal metastases." Rain R. Chen, Mingo M. H. Yung, Yang Xuan, Shijie Zhan, Leanne L. Leung, Rachel R. Liang, Thomas H. Y. Leung, Huijuan Yang, Dakang Xu, Rakesh Sharma, Karen K. L. Chan, Siew-Fei Ngu, Hextan Y. S. Ngan & David W. Chan